9 new oncology trials approved in Europe
 |
Oncology Hero |
9 new oncology trials approved in Europe
Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe.
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib with Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer
| Sponsor: Celcuity Inc. | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
| Sponsor: Voronoi Inc. | Phase: 1, 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestPhase III ASP2138 with chemotherapy and pembrolizumab in CLDN18.2-positive HER2-negative advanced gastric or GEJ cancer
| Sponsor: Astellas Pharma Global Development Inc. | Phase: 3 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 1/2 Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of ARV-6723 Administered as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
| Sponsor: Arvinas Operations Inc. | Phase: 1, 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)
| Sponsor: Verastem Inc. | Phase: 2 |
Interested in offering this trial to suitable patients?
Register Investigator InterestA Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with Bevacizumab Compared with Platinum Doublet with Bevacizumab in Participants with Platinum-Sensitive Ovarian Cancer
| Sponsor: Glaxosmithkline Research & Development Limited | Phase: 3 |
Not accepting new sites
A Phase Ib/II, open-label, safety and tolerability trial of intravenous obrixtamig in combination with pumitamig and standard of care (carboplatin, etoposide) in patients with extensive stage small cell lung carcinoma.
| Sponsor: Boehringer Ingelheim International GmbH | Phase: 1, 2 |
Not accepting new sites
A Study of RO7821657 in Participants with Solid Tumors
| Sponsor: F. Hoffmann-La Roche AG | Phase: |
Not accepting new sites
A Randomised, Double‑Blind, Placebo‑Controlled, 2‑Cohort, Phase III Study of Saruparib Combined with Physician’s Choice of Androgen Receptor Pathway Inhibitor in Patients With Metastatic Hormone‑Sensitive Prostate Cancer, Previously Treated With Docetaxel or PSMA‑directed 177Lutetium‑Containing Therapy Without Disease Progression, and With Prostate‑Specific Antigen ≥ 0.2 ng/mL: EvoPAR Prostate‑05
| Sponsor: AstraZeneca AB | Phase: 3 |
Not accepting new sites
Oncology Hero Trial Feed connects oncology professionals with relevant clinical trials.
For qualified healthcare and research professionals. Registration expresses investigator interest; it is not patient enrollment.
Oncology Hero
Sharing the latest updates in oncology
Oncology Hero 12 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials and investigator opportunities in Europe. EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC. Sponsor: European Organisation For Research And Treatment Of Cancer Phase:...
Oncology Hero 11 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients Sponsor: Centre Leon Berard Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest PD-1 blockade alone versus...
Oncology Hero 8 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. Breast density reduction with linzagolix or bilastine in premenopausal women at high risk of breast cancer: a phase II clinical trial. Sponsor: Consorci Mar Parc De Salut De Barcelona Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest A phase 2 study to assess efficacy of induction...